Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial.

Neuropathy is a dose limiting side effect of taxanes which may impact the quality of life and treatment outcomes. This randomized placebo-controlled double-blinded clinical trial was carried out to assess the efficacy of gabapentin in preventing chemotherapy induced neuropathy. Women with breast cancer were randomized into two groups of paclitaxel chemotherapy with gabapentin 300 mg/three times a day orally or placebo for 2 weeks started at day 1 of each paclitaxel cycle. Two groups were compared based on the relative frequency of neuropathy and change in nerve conducting velocity (NCV). Twenty women were assigned to each study arm. The majority of the neuropathy in gabapentin group was grade 1 in all of the four cycles with no event of ≥grade 3 neuropathy in this group. Compared to the placebo, the rate of 2nd and 3rd grade neuropathy was significantly lower in the gabapentin group (P = 0.000). The change in NCV after four cycles of paclitaxel was significantly lower in the gabapentin group compared to the placebo group (17.7% vs 61.0% decline in NCV for sural and 21.9% vs 62.5% declines in NCV for peroneal nerve). Gabapentin given with paclitaxel is effective in the prevention of intermediate and high grade neuropathies both objectively and subjectively.

Vestibular evoked myogenic potential for diagnoses of multiple sclerosis: is it beneficial?

AIM: To determine the sensitivity of the vestibular evoked myogenic potential (VEMP) in multiple sclerosis (MS) patients as well as its relation to clinical signs and symptoms, course of the disease and other evoked potentials. METHODS: This case-control study was conducted on 40 subjects (20 MS patients and 20 healthy participants). Participants were selected from Imam Khomeini Hospital, Tehran, Iran. Two hundred stimuli (clicks of 0.1 ms of duration and 2 Hz frequency) were applied to each ear. These stimuli were repeated in two consecutive cycles. In order to evaluate the reproducibility the stimulation intensity of 95dBNHL was applied. During the test, individuals were requested to be seated on a chair and rotate their head to the opposite side of the stimulated ear to activate the ipsilateral sternocleidomastoid muscle (SCM). RESULTS: A biphasic, initially positive, p13-n23 wave pattern was found in all patients. All of the parameters, including latencies and amplitudes fit the normal Kolmogorov-Smirnov (KS) distribution. Fourteen (70%) patients reported abnormal results, and VEMP abnormality was significantly related to disease duration also. In addition, there was a significant correlation between abnormality of VEMP and abnormality of visual evoked potential (VEP) as well as the abnormality of VEMP and brainstem auditory evoked potential (BAEP). CONCLUSION: Vestibular evoked myogenic potential has a high sensitivity (70%) in MS patients, and VEMP could be recommended as a useful complementary neurophysiological method to evaluate the MS patients.

Peripheral neuropathy response to erythropoietin in type 2 diabetic patients with mild to moderate renal failure.

This study assessed the added effect of 6 months of erythropoietin (EPO) administration in patients suffering from diabetic neuropathy with mild to moderate chronic kidney disease (CKD) managed with gabapentin. Twenty diabetic patients with mild to moderate CKD were included; 12 in gabapentin and 8 in EPO+gabapentin group. The subjects underwent nerve conduction studies (NCS) at the initiation of the investigation and after 6-month treatment. NCS were made in deep and superficial peroneal, tibial, and sural nerves. After 6 months, in both the groups, proximal motor latency (PML) nonsignificantly improved in deep peroneal and tibial nerves; conversely, dorsal motor latency (DML) got slightly impaired in these two nerves. A nonsignificant disruption and improvement was observed in deep peroneal and tibial motor nerve conduction velocity (MNCV), respectively, in gabapentin group. Although the F-wave of tibial and deep peroneal nerves remained stable in gabapentin group, a nonsignificant improvement was observed in EPO+gabapentin group. H-reflex of tibial nerve and all the evaluated parameters of sural and superficial peroneal nerves remained constant in all patients. Thus, it can be concluded that 6-month administration of EPO+gabapentin, or gabapentin alone in mild to moderate CKD patients with diabetic neuropathy could not improve nerve performance.

Vestibular evoked myogenic potentials of haemodialysed patients with end stage renal disease.

End stage renal disease (ESRD) can cause malfunction of multiple organs, including auditory and vestibular systems. During recent years, a significant amount of research has demonstrated the direct involvement of the otolith organs in stabilizing body and gaze which led to the development of specific functional tests. Stable gaze and body are more important in patients with ESRD, as they have an increased risk of bone fracture. The aim of this study was to investigate saccule and related neural pathways in haemodialysed patients with chronic renal failure. Twenty patients (40 ears) with ESRD were tested for vestibular evoked myogenic potentials (VEMP). Results were compared with those of 16 healthy controls (32 ears). VEMP response was significantly different between subjects and patients with ESRD. There was a significant difference between the presence and absence of VEMP waves in ESRD patient when compared with creatinine levels.